Commit Biologics announced the final close of a $60 million seed round on November 17 to move its first experimental drug toward human trials. The Danish biotech expects first patient dosing in early 2028.
Ackermans & van Haaren led the final close, with AbbVie Ventures and M Ventures joining as new investors. The money will fund studies and a regulatory filing for COM002, plus work to prepare a second program for clinical development.
At its January 2025 seed extension, Commit was still working toward candidate selection and said its cash would last into late 2026. It selected COM002 on November 12, initially targeting non-Hodgkin lymphoma that has returned or resisted treatment, with autoimmune indications planned later.
Commit designs antibodies that bring C1q, an immune-system protein, to selected cells and trigger their destruction. Its BiCE platform aims to do that independently of T cells, a distinction from therapies that enlist those cells to attack disease.
In November 2025, Commit reported that a single dose of a BiCE candidate depleted B cells in primates for more than four weeks, with no adverse clinical observations or cytokine release. Those animal findings do not establish safety or efficacy in patients.